Q3 FY2026 · ended Sep 30, 2026 · Revenue $874.00M, +1.6% YoY · Filed Nov 5, 2026
Bruker Corporation (BRKR) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $874.0 million and a net loss of $111.8 million. Free cash flow was $96.7 million. As of Sep 30, 2026 it held $119.7 million in cash and investments and $1.7 billion in total debt.
Revenue
$874.00M
+1.6% vs year-ago quarter
Net income
$-111.80M
-87.6% vs year-ago quarter
Operating cash flow
$118.20M
+456.0% vs year-ago quarter
Free cash flow
$96.70M
+278.7% vs year-ago quarter
EPS
$-0.81
-97.6% vs year-ago quarter
Dividend per share
$0.05
+0.0% vs prior quarter
Shares outstanding
152.72M
+0.9% vs year-ago quarter
Net cash
$-1.59B
Q3 FY2026
Operating margin
-2.0%
TTM
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BRKR (Nasdaq), BRKRP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Billerica, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1109354
- Former names
- BRUKER BIOSCIENCES CORP (until Feb 27, 2008); BRUKER DALTONICS INC (until Jul 2, 2003)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- 10x Genomics, Inc. TXG
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $874.0M | $838.5M | $823.4M | $977.2M | $860.5M |
| Operating income | -$91.0M | -$65.3M | $10.2M | $76.3M | -$51.8M |
| Net income | -$111.8M | -$52.0M | $14.4M | $26.0M | -$59.6M |
| Diluted EPS | -$0.81 | -$0.41 | $0.02 | $0.10 | -$0.41 |
| Operating cash flow | $118.2M | -$77.4M | $71.2M | $229.8M | -$33.2M |
| Free cash flow | $96.7M | -$106.2M | $47.0M | $207.2M | -$54.1M |
| Total assets | $5.8B | $6.1B | $6.1B | $6.2B | $6.4B |
| Total liabilities | — | — | — | $3.7B | — |
| Stockholders' equity | $2.3B | $2.4B | $2.5B | $2.5B | $2.4B |
| Cash and investments | $119.7M | $184.9M | $133.4M | $298.8M | $293.1M |
| Total debt | $1.7B | $1.8B | $1.7B | $2.1B | $2.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 1004 Bruker Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.